Adze1.C
AXP000063.1 · Oncolytic virus
- Platform
- adenovirus
- Originator
- Adze Biotechnology
- Sponsor
- Adze Biotechnology Australia
Names
| Name | Type | Source |
|---|---|---|
| Adze1.C | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus (serotype not reported)
- Replication
- conditionally replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07086105 | A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma | Recruiting | Phase 1 | 2025-10-01 | 2027-10-01 | 30 | Metastatic Melanoma |
Recent changes
No changes recorded in its trials yet.
Notes
Oncolytic adenovirus, trial NCT07086105 (Australia). Construct not described in the registration.
How to cite
Adze1.C (AXP000063.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000063.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.